Merck and NewLink begin Phase II/III trial of Ebola vaccine candidate in Sierra Leone

Merck and NewLink Genetics have initiated the third, late-stage, clinical trial of their Ebola vaccine candidate, rVSV-ZEBOV-GP (V920), in Sierra Leone.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news